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Abstract. Previous studies have demonstrated that the 
leukocyte integrin Mac-1 adheres to several cell surface 
and soluble ligands including intercellular adhesion 
molecule-I, fibrinogen, iC3b, and factor X. However, 
experiments with Mac-l-expressing transfectants, puri- 
fied Mac-l, and mAbs to Mac-1 indicate the existence 
of additional ligands. In this paper, we demonstrate a 
direct interaction between Mac-1 and heparan sulfate 
glycans. Heparin affinity resins immunoprecipitate 
Mac-l, and neutrophils and transfectant cells that ex- 
press Mac-1 bind to heparin and heparan sulfate, but 
not to other sulfated glycosaminoglycans. Inhibition 
studies with mAbs and chemically modified forms of 
heparin suggest the I domain as a recognition site on 
Mac-1 for heparin, and suggest that either N- or O-sul- 
fation is sufficient for heparin to bind efficiently to 
Mac-1. Under conditions of continuous flow in which 
heparins and E-selectin are cosubstrates, neutrophils 
tether to E-selectin and form firm adhesions through a 
Mac-l-heparin interaction. 
I 
N many immune responses, neutrophils are among the 
first cells to exit from the circulatory system and traf- 
fic to an inflammatory site. For this to occur, neutro- 
phils must attach to endothelial cells, change shape, dia- 
pedese,  and  migrate.  Over  the  past  few  years,  several 
families  of surface  receptors on the  neutrophil  and  en- 
dothelial cell surface  that  facilitate movement from the 
bloodstream have been identified. Selectins form transient 
attachments that allow neutrophil rolling on inflamed en- 
dothelium (11, 66). G-protein-coupled receptors bind sol- 
uble inflammatory molecules (25, 66), and signal integrins 
to strengthen attachment to endothelial cells, and initiate 
movement to the underlying tissue (11, 66). The details of 
neutrophil migration to the  target  site  are  less  clear. A 
chemotactic gradient of soluble or tethered inflammatory 
peptides or lipids augments the adhesiveness of surface re- 
ceptors and reorganizes the cytoskeleton. To move direc- 
tionally, neutrophils adhere transiently to molecules in the 
extracellular environment;  although  the  matrix  contains 
an abundant number of adhesive proteins, proteoglycans, 
and  carbohydrates,  it  is  unknown  which  participate  in 
chemotaxis. 
The leukocyte integrins comprise a subfamily of related 
cell-surface glycoproteins that coordinate adhesive func- 
tions including leukocyte migration (12, 65). The members 
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of this family include lymphocyte function-associated anti- 
gen-1 (CDlla/CD18), Mac-1 (CDllb/CD18)  and p150,95 
(CDllc/CD18).  They share  a  common 13 subunit that is 
noncovalently associated with unique, but closely related, 
~x subunits (32). The et subunits share two features in their 
extracellular region, a 200--amino acid inserted I  domain 
and three tandem EF handlike putative divalent cation- 
binding repeats (32). 
Mac-1 is expressed primarily on myeloid cells. Experi- 
ments  with  blocking  mAbs  and  with  neutrophils  from 
patients with  a  genetic deficiency of leukocyte integrins 
demonstrate a role for Mac-1 in an array of adhesive inter- 
actions that include myeloid cell adhesion to, and transmi- 
gration across, endothelium or epithelium, neutrophil ho- 
motypic adhesion and chemotaxis, myeloid cell adhesion 
to serum-coated substrates, and the binding and phagocy- 
tosis of opsonized particles (4, 8, 52, 54, 63, 72). Mac-1 sus- 
tains these interactions by binding to several cell surface 
and soluble ligands including intercellular adhesion mole- 
cule (ICAM)-I 1, fibrinogen, iC3b, and factor X (1, 2, 8, 19, 
63, 72, 73). Recent experiments with mAbs, integrin chi- 
meras,  and  soluble  protein  fragments  define  the  200- 
amino acid I domain on Mac-1 as a recognition site for at 
least three of its ligands (21, 70, 75). 
Although  these  four  ligands  subserve  many  Mac-I- 
dependent adhesive functions, they do not account for the 
entirety of its adhesive interactions. For example, a recep- 
1. Abbreviations  used in this paper: fMLP, formylmethionyUeucylphenyl- 
alanine; ICAM, intercellular adhesion molecule; LAD, leukocyte adhe- 
sion deficiency. 
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ICAM-1 has been suggested, but not yet identified (19, 39, 
52). A  counterreceptor on neutrophils that participates in 
Mac-l-dependent  homotypic  adhesion  remains  postu- 
lated, but uncharacterized (4, 54). Finally, the chemotaxis 
of neutrophils requires Mac-l, but no extracellular matrix 
ligand  has  been  documented.  Several groups,  including 
our own, have attempted unsuccessfully to raise blocking 
mAbs or to identify novel cDNAs that confer adhesion to 
purified or cellular Mac-1. Moreover, a recent study sug- 
gests that the adhesion of bone marrow cells to stromal fi- 
broblasts may occur, in part through a heparan sulfate in- 
teraction with  Mac-1  (13).  In  this  report, we  document 
heparin and heparan sulfate as glycosaminoglycan, adhe- 
sive ligands for the leukocyte integrin Mac-1. Using data 
from  static  and  shear  flow  adhesion  assays  we  suggest 
novel adhesive  pathways  through  which  Mac-l-heparin 
interactions may mediate neutrophil trafficking from the 
circulatory system to an inflammatory site. 
Materials and Methods 
Glycosaminoglycans 
High molecular weight (tool wt  =  13,000-15,000) porcine intestine mu- 
cosal heparin and low molecular weight (tool wt =  5,000) bovine intestine 
mucosal heparin were purchased from Calbiochem Corp. (La Jolla, CA). 
Chemically modified forms of heparin  were  obtained  from Seikagaku 
Koygo Co. (Tokyo, Japan). Heparan sulfate (tool wt = 7,500) from bovine 
intestinal mucosa, keratan sulfate from bovine cornea, and all forms of 
shark cartilage chondroitin sulfate (A, B, C) were purchased from Sigma 
Chemical Co. (St. Louis, MO). 
mAbs 
The following mAbs were used from ascites: TS1/22 (anti-CDlla)  (60), 
Mn41  (anti-CD11b) (22),  LPM19c (anti-CD11b)  (69), 44a (anti-CD11b) 
(5),  OKM9  (anti-CDllb)  (72),  TMG-65  (anti-CDllb)  (69),  14B6E.2 
(anti-CDllb)  (69),  the CBRM1  series (anti-CDllb:  M1/1, M1/2, M1/4, 
M1/9, M1/10, M1/13, M1/16, M1/17, M1/18, M1/20, M1/21, M1/22, M1/23, 
M1/24, M1/25, M1/26, M1/27, M1/28, M1/29, M1/30, M1/31, M1/32, M1/33, 
M1/34)  (21),  CBRp150,95/4G1  (anti-CDllc)  (67),  and  TS1/18  (anti- 
CD18) (60). The following mAbs were used as purified IgG: W6/32 (anti- 
HLA A, B, C) (7), OKM1 (anti-CD11b) (72), LM2/1 (anti-CDllb) (45), 
R15.7 (anti-CD18, a gift of Dr. R. Rothlein, Boehringer Ingelheim Ltd., 
Ridge  field, CT) (23), and DREG-56 (anti-L-selectim a gift of Dr. T. Kish- 
imoto, Boehringer Ingelheim Ltd.) (33). 
Tissue Culture,  Transfection,  and Cell Preparation 
Peripheral blood neutrophils from healthy volunteers or patients with leu- 
kocyte  adhesion  deficiency  (LAD)  were  isolated  from  whole  venous 
blood by dextran sedimentation, Ficoll gradient centrifugation, and hypo- 
tonic lysis (46).  Before experimentation, cells were maintained at room 
temperature in HBSS, 10 mM Hepes, pH 7.3, and 1 mM MgCl  2 in polypro- 
pylene tubes (2097;  Falcon Labware, Becton Dickinson &  Co., Lincoln 
Park, NJ). In some experiments, neutrophils were maintained in HBSS, 10 
mM Hepes, pH 7.3, 1 mM MgCl  2, and 1 mM CaClz. 
CHO cell stable transfectants that express Mac-l, p150,95 or ICAM-1 
have been described (21).  These cells were maintained in c~-MEM,  10% 
dialyzed FCS, 16 p.M thymidine, 0.05 txM methotrexate, 2 mM glutamine, 
and 50 ~g/rnl gentamicin. 
Protein Purification  and SDS Gel Electrophoresis 
As described (51), the procedure for isolating cytochrome b559 and Mac-1 
includes solubilizing stimulated granulocyte membranes in 2% n-octylq3- 
D-glucopyranoside followed by passage of the detergent extract over a col- 
umn of wheat germ agglutinin-Sepharose 4B. After washing, the bound 
proteins were eluted from the wheat germ agglutinin-Sepharose 4B with a 
membrane  resuspension buffer  (100  mM  KCI,  10  mM NaCl,  10  mM 
Hepes, pH 7.3,  1 mM EDTA, 1 mM PMSF,  10 ~g/ml chymostatin, 200 
mM N-acetyl glucosamine, 200 p~g/ml chitobiose, 0.4 M  NaC1,  and 0.2% 
Triton X-100). The eluate was concentrated and diluted 10-fold to reduce 
the salt concentration to 50 mM, and passed over a 5-ml column of hep- 
arin-Ultrogel  (LKB  Instruments Inc.,  Bromma,  Sweden).  Cytochrome 
b559 and Mac-1 were eluted from the heparin column with a gradient of 
increasing NaC1 containing 0.1% Triton X-100. Peak heparin eluate frac- 
tions were  subjected to  SDS-PAGE  on linear polyacrylamide gradient 
gels (8-16%) followed by either staining or electrophoretic transfer onto 
nitrocellulose as described (51). 
The purification of Mac-1 by LM2/1 immunoaffinity chromatography 
has been described (19).  Approximately 2-5 ~g of purified Mac-1 in 300 
mM NaCI, 50 mM triethanolamine, 0.1 M  Tris, 1% n-octyl-[3-o-glucopy- 
ranoside, pH 8.0,  was diluted 20-fold with 10 mM Hepes, pH 7.4,  0.1% 
Triton X-100, 35 mM NaCI, and incubated for 3 h at 4°C with either 50 p~l 
of heparin-Ultrogel or, as a control, Ultrogel alone. After washing with 40 
mM NaCI, 10 mM KCI, 10 mM Hepes, pH 7.4,  0.1%  Triton X-100, the 
beads were eluted for 1 h  at 4°C with 0.5 ml of 400 mM NaCI, 100 mM 
KC1, 10 mM Hepes, pH 7.4, and 0.1% Triton X-100. The eluates were con- 
centrated 10-fold using a 30-kD cutoff microconcentrating device (Ami- 
con Corp., Danvers, MA) and subjected to SDS-PAGE followed by silver 
staining as described above. 
Static Adhesion Assays 
The neutrophil binding assay was based on a previously published proto- 
col (20). Purified heparins (5 mg/ml in PBS), chondroitin sulfates (A, B, or 
C, 5 mg/ml in PBS), or fibrinogen (2 mg/ml in PBS; Sigma Chemical Co.) 
were spotted (25 t~l) onto 6-cm bacterial petri dishes (1007; Fisher Scien- 
tific Co., Pittsburgh, PA) for 90 rain at room temperature. Protein or gly- 
cosaminoglycan was removed, and the plates were blocked with the deter- 
gent Tween 20. Neutrophils (4 ×  106 cells in 1 ml) were resuspended in 
HBSS, 10 mM Hepes, pH 7.3,  1 mM MgCI2, and for some experiments, 
preincubated with mAbs (1/200 dilution of ascites or 20 ~g/ml purified 
mAb) or with soluble glycosaminoglycan  for 15 min at room temperature. 
In some experiments, 1 mM CaCI~ was added to the HBSS binding buffer. 
Subsequently, cells were  added  to  the petri  dishes in  the presence of 
formylmethionylleucylphenylalanine (fMLP)  (10 -7 M, final volume of 3 
ml) and allowed to adhere for 3.5 min. Nonadherent cells were removed, 
and binding was quantitated as described (20, 21). 
The binding of CHO cell transfectants is a modification of a previously 
described protocol (21). Heparins and chondroitin sulfates were adsorbed 
to 6-cm petri dishes. After a 90-rain incubation at room temperature, non- 
specific binding sites were blocked with a 0.5% heat-treated BSA solution 
(PBS, 1 mM MgC12, 0.025% NAN3). CHO cell transfectants, after detach- 
ment from tissue culture plates with HBSS, 10 mM Hepes, pH 7.3, 5 mM 
EDTA, were washed twice, resuspended (8 x  105 cells/ml) in HBSS, 10 
mM Hepes, pH 7.3,  1 mM MgClz, 0.5% heat-treated BSA, and bound to 
glycosaminoglycan-coated petri dishes for 20 rain at room temperature. 
Nonadherent  cells were  removed,  and binding was  quantitated  as  de- 
scribed  (21).  In some experiments, the number of nonviable, adherent 
transfectants was determined by staining with PBS, 0.4% trypan blue, and 
this value was subtracted. 
Laminar Flow Adhesion Assays 
Purified heparin (5 mg/ml) or heparan sulfate (10 mg/ml) was spotted on 
bacterial petri dishes (Nunc Inc., Naperville, IL) and blocked with Tween 
20  as  described  above.  Control  substrates were  prepared  by  blocking 
dishes solely with Tween 20. Soluble recombinant E-selectin (36) (a gen- 
erous gift of Dr. R. Lobb, Biogen, Cambridge, MA) was diluted (0.4 ~g/ml 
in 50 mM NaHCO  3, pH 9.1) and absorbed on bacterial petri dishes for 2 h 
at room temperature. The substrate was washed twice with PBS, and hep- 
arin (5 mg/ml) or control PBS solution was adsorbed onto the E-selectin- 
coated substrate for 10 h  at room temperature. The substrate was then 
blocked with 0.2% Tween 20, PBS for 60 min at room temperature. 
The laminar flow assays were performed in a parallel wall flow cham- 
ber as described previously (35, 36). Briefly, a petri dish slide on which pu- 
rified heparin, heparan sulfate, and/or recombinant E-selectin had been 
absorbed was assembled as the lower wall of the parallel flow chamber 
and mounted on the stage of an inverted phase-contrast microscope (Dia- 
phot-TMD; Nikon Inc., Instrument Division, Garden City, NY). Cells that 
tethered or arrested were quantitated by analysis of images videotaped 
with a video camera (TEC-470 CCD; Optronics Engineering, Goleta, CA) 
and Hi 8 recorder (CVD-1000; Sony Corp., Park Ridge, NJ). Peripheral 
blood neutrophils were resuspended (5  ×  105 cells/ml) in binding media 
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or presence of IL-8 (50 ng/ml, Genzyme Corp., Cambridge, MA) and im- 
mediately perfused through the chamber at different flow rates to obtain 
the indicated shear stresses at the chamber wall. In experiments with a sin- 
gle divalent cation, neutrophils were washed in HBSS, 10 mM Hepes, pH 
7.4, 10 mM EDTA and resuspended in HBSS, 10 mM Hepes, pH 7.4, 2 
mM CaC12. 
For mAb inhibition studies, neutrophils (107 cells/ml)  were incubated 
in HBSS, 10 mM Hepes, pH 7.4 for 5 min at room temperature with 30 Ixg/ 
ml of purified mAbs (CBRM1/29,  DREG-56, W6/32) or a 1:30 dilution of 
ascites  (CBRM1/34).  The cell suspension was diluted in a 20-fold volume 
of binding media and immediately perfused into the  flow chamber. In 
some experiments, to assess the requirement of active metabolism on inte- 
grin-mediated adhesion, cells were preincubated for 5 min in binding me- 
dia supplemented with 0.5 % NaN  3. 
Neutrophil binding to heparin or control substrates at subphysiologic 
shear stress was determined by counting the number of ceils that attached 
over a 3-min period of continuous shear flow for a given field of view (0.43 
mm2). Detachment assays were performed on cells tethered at subphysio- 
logic shear flow to purified heparin. The shear flow was increased every 
10 s to a maximum of 14.6 dyn/cm  2, in 2-2.5-fold  increments and the num- 
ber of cells  remaining bound at the end of each 10-s interval was deter- 
mined. 
Neutrophil tethering to E-selectin substrate coimmobilized with hep- 
arin was performed under physiologic shear flow (1.05 dyn/cm2), and the 
rate of cell tethering (number of events lasting at least 2 s/min per 0.43 
mm  2 field) was determined. No tethering was observed under these condi- 
tions to substrates coated with heparin alone. Rolling velocities  of neutro- 
phils  (30-35  per field)  that  tethered  under flow were determined  at  a 
shear stress of 1.5 dyn/cm  2 by cell displacements measured over 5-s inter- 
vals. For comparison of effects  of mAbs or chemical treatments, identical 
fields  were used for binding experiments to ensure that results reflected 
uniform site density of immobilized adhesive molecules. 
Results 
Previously, we identified ICAM-1 on endothelial cells as a 
counterreceptor for Mac-1 (19).  In the course of these ex- 
periments, we observed that unstimulated endothelial cells 
bind  to purified Mac-1 even in the presence of blocking 
mAbs to ICAM-1. Since Mac-1 does not bind to ICAM-2 
(15, 19), we postulated the existence of an additional adhe- 
sive ligand on endothelium for Mac-1.  Subsequently, we 
found  several  mesenchymally  derived  tumor  cell  lines 
(e.g.,  RD 3/5 and FS 12/3) that lack or had low expression 
of ICAM-1, ICAM-2, and  ICAM-3 (15,  16),  but  adhere 
strongly to  purified  Mac-1  (Diamond,  M.  S.,  and  T.  A. 
Springer, unpublished observations). Because we were un- 
able to clone a cDNA or make function blocking antibodies 
against this putative ligand, we hypothesized a highly con- 
served molecule. Two candidates were proteoglycans and 
sialylated carbohydrates, molecules that function broadly 
in cell adhesion in the extracellular matrix and on the cell 
surface. 
While purifying cytochrome b559 from solubilized gran- 
ulocytes, a "contaminating" 150-kD protein was observed 
that eluted from a heparin affinity resin under conditions 
of moderately high ionic strength (250 mM NaC1; Fig. 1, 
lane 4) (51).  Because of the similarity of molecular weight 
to Mac-l, this eluate was immunoblotted. Both mAbs (Fig. 
1, lane 3) and polyclonal antisera (data not shown) against 
CDllb identified the 150-kD protein as a subunit of Mac-1. 
Additionally, functionally active Mac-1 binds to immobi- 
lized heparin  directly; Mac-1 purified  by immunoaffinity 
chromatography (19) is reprecipitated by heparin-Ultrogel 
(Fig.  1, lane 5), but not by Ultrogel alone (Fig. 1, lane 7). 
Scanning densitometry showed that 73%  of the  purified 
Mac-1 bound to Heparin-Ultrogel (data not shown). 
Figure  1.  Immunoblotting  and  SDS 8-16%  gradient  PAGE of 
Mac-1 purified from detergent-solubilized  granulocyte lysates by 
immunoaffinity  or  heparin  affinity chromatography.  Lane  1, 
Mac-1 purified by mAb (LM2/1) affinity chromatography, immu- 
noblotted with anti-Mac-1 mAb (44a), and visualized with perox- 
idase-conjugated goat anti-mouse  IgG; lane 2, Mac-1 purified by 
mAb  (LM2/1) affinity  chromatography,  immunoblotted  with 
negative control mAb, and visualized with peroxidase-conjugated 
goat anti-mouse; lane 3, immunoblot with anti-Mac-1 mAb (44a) 
of the peak heparin eluate fraction from the purification of gran- 
ulocyte cytochrome b559 (see Materials and Methods), and visu- 
alized with peroxidase-conjugated goat anti-mouse  IgG; lane 4, 
Coomassie stain of SDS-PAGE of peak heparin eluate fraction 
shown as an immunoblot in lane 3; lanes 5--8; silver staining of re- 
duced SDS-PAGE of purified Mac-1 after binding and elution 
from heparin-Ultrogel (see Materials and Methods); lane 5, Mac-1 
eluted (400 mM NaC1) from heparin-Ultrogel  showing the char- 
acteristic 150 and 95 kD subunits; lane 6, SDS denaturation  of 
heparin-Ultrogel  matrix after high salt elution of Mac-1 demon- 
strating minimal residual integrin on the matrix; lane 7, Control 
high salt (400 mM NaCI) eluate  from Ultrogel after incubation 
with purified Mac-1 demonstrating a lack of nonspecific binding 
of the two subunits of Mac-l; lane 8, SDS denaturation of the U1- 
trogel matrix after high salt elution demonstrating no residual in- 
tegrin on the matrix. 
To assess the significance of this biochemical interaction 
between Mac-1 and heparin, we assayed neutrophil adhe- 
sion  to  different  purified  glycosaminoglycans.  Resting 
neutrophils bind weakly to both low (mol wt =  5,000) and 
high (mol wt =  13,000-15,000) molecular weight forms of 
heparin, but not to chondroitin sulfate A, B, or C (Fig.  2, 
and  data  not  shown).  Stimulation  with  the  chemotactic 
peptide  fMLP enhances  adhesion of neutrophils to hep- 
arin,  but  not  to  chondroitin  sulfate;  in  parallel  experi- 
ments, an equivalent number of activated neutrophils bind 
to ICAM-1 and fibrinogen (data not shown). To confirm 
that Mac-1 on neutrophils mediates the adhesion to hep- 
arin, we tested neutrophils from patients who have the ge- 
netic disease LAD which is characterized by an absence of 
Mac-1 on leukocytes (3).  LAD patient neutrophils do not 
adhere to any form of heparin or chondroitin sulfate in the 
absence or presence of fMLP (Fig.  2)  or in buffers that 
contain only Mg  2÷ or both Mg  2+ and Ca  2+ (data not shown). 
Inhibition experiments  with  mAbs sustain  the  role  of 
Mac-1 in neutrophil adhesion to heparin. Blocking mAbs 
to Mac-1  (LPM19c) but not to LFA-1 (TS1/22),  p150,95 
(CBRp150,95/4G1), or L-selectin (DREG-56) abolish ad- 
hesion to heparin (Fig. 3; see Fig. 7). A  panel of mAbs to 
Mac-1 for which epitopes have been mapped on the a  sub- 
unit, and which have been tested for inhibition of binding 
to other ligands (21),  was used to localize the recognition 
site for heparin (Table I). mAbs to the I domain inhibited 
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Peripheral  blood  neutrophils  from  healthy  volunteers  or  LAD 
patients were resuspended (4 ×  106 cells/ml) and added to 60-mm 
petri dishes coated with spots of chondroitin sulfate C, or low or 
high molecular weight  heparin.  Binding in  the  absence  or pres- 
ence of 10  -7 M  fMLP was for 3.5 rain  at room temperature,  and 
unbound cells were removed by 10 washes with a Pasteur pipette. 
Bound  cells were  quantitated by visually scoring the number of 
cells in five microscopic fields (× 100). One representative experi- 
ment of four is shown, and bars indicate standard deviations. 
binding with a  mean of 57.3  --- 24.4%,  whereas mAbs to 
the COOH-terminal region blocked with a mean of 11.0 -+ 
9.8%. 5 of 18 mAbs that mapped to the I domain blocked 
strongly (>80%),  whereas no mAb that  localized to the 
COOH-terminal region showed >30% inhibition. The one 
mAb  (CBRM1/20)  that  mapped directly to  the  divalent 
cation-binding region had little inhibitory effect. The one 
mAb that mapped to sites in both the NH2-terminal and 
divalent cation-binding regions blocked 63%  of the bind- 
ing.  Collectively, these  data  suggest a  recognition  site in 
the I domain on Mac-1 for heparin. 
To eliminate the possibility that mAbs to Mac-1 inhibit 
neutrophil  adhesion  by  an  indirect  effect,  we  examined 
Figure 3.  The effect Of mAb  on neutrophil adhesion to high mo- 
lecular weight heparin. Peripheral  blood neutrophils were resus- 
pended (4 ×  106 cells/ml), preincubated at room temperature for 
15 min with mAbs, and added to 60-mm petri dishes coated with 
heparin  in  the  absence  or  presence  of  10 -7 M  fMLP.  The  cell- 
binding assay, washing, and quantitation  were performed as de- 
scribed  in Fig.  2.  mAbs: Media (no mAb), anti-Mac-1  (OKM1, 
LPM19c), anti-p150,95 (CBRp150,95/4G1),  anti-LFA-1 (TS1/22). 
One representative experiment of three is shown, and bars indi- 
cate standard deviations. 
Table I. Summary of lnhibition of Neutrophil Adhesion to 
Heparin by mAbs and Comparison with Structural Epitope 
mAb  Epitope  Percent inhibition +- SEM 
LPM19c 
OKM9 
LM2/1 
TMG-65 
Mn41 
14B6E.2 
CBRM1/1 
CBRM1/2 
CBRM1/4 
CBRM1/13 
CBRM1/21 
CBRM1/22 
CBRM1/24 
CBRM1/27 
CBRM1/29 
CBRM 1/31 
CBRM1/33 
CBRM1/34 
OKM1 
CBRM1/9 
CBRM1/10 
CBRM1/16 
CBRM1/17 
CBRM1/18 
CBRM1/23 
CBRM1/25 
CBRM1/26 
CBRM1/30 
CBRM1/32 
CBRM1/20 
CBRM1/28 
CBRp 150,95/4G 1 
TS1/18 
R15.7 
I domain 
I domain 
I domain 
I domain 
I domain 
I dommn 
I domain 
I domain 
I domain 
I domain 
I domain 
I domain 
I dommn 
I dommn 
I domam 
I domain 
I domain 
I domain 
COOH-terminal 
COOH-terminal 
COOH-terminal 
COOH-terminal 
COOH-terminal 
COOH-terminal 
COOH-terminal 
COOH-terminal 
COOH-terminal 
COOH-terminal 
NH2-cation 
cation 
? 
p150,95 
CD18 
CD18 
94.1  +--  1 
45.4 --- 2 
29.1  ---9 
82.0 z  3 
84.5 --- 9 
28.8 --+ 8 
57.4 +-- 8 
41.6--- 7 
27.8 --- 11 
8.5---  13 
73.3 -+  15 
64.2 ----- 13 
34.4 --- 14 
86.3 ---+ 9 
69.6 ----- 8 
60.5 ----- 8 
55.7 -+ 9 
88.0 ----- 5 
2.8 -+  14 
--6.2 -+  13 
24.0 -+ 5 
10.8  --. 10 
10.8 ---+ 15 
9.8 --+ 17 
6.1--+1 
3.7-----5 
22.2 ----- 17 
26.4 --- 6 
62.8 -+  13 
13.1  -+ 2 
12.3  -+ 6 
--3.3 -+  10 
16.8  -+ 0.5 
60.2 -+ 7 
Neutrophils were prepared as described in Fig. 3. Results are the average of three to 
five independent experiments. Epitopes are assigned according to their binding to a 
series of Mac- 1/p  150,95 chimeras as described (21). 
transfectant  cell  binding  to  heparin.  CHO  cells  that  ex- 
press Mac-1  adhere strongly to heparin but not to chon- 
droitin sulfate (Fig. 4 A); adhesion is specific as mAbs to 
Mac-l,  but  not  to  LFA-1  block  (Fig.  4  B).  In  contrast, 
CHO cells that express ICAM-1  do not bind to heparin. 
Thus,  Mac-1  is  both  necessary and  sufficient for attach- 
ment  to  heparin.  Interestingly,  CHO  cells  that  express 
p150,95 bind to heparin, although at lower efficiency. 
To  evaluate  the  interaction  more  quantitatively,  we 
tested  soluble  heparin  for  its  ability  to  inhibit  Mac-l- 
dependent  neutrophil  adhesion  to  immobilized  heparin 
(Fig. 5). Preincubation of neutrophils with soluble heparin 
dose  dependently  inhibited  adhesion  to  heparin  (inhibi- 
tion constant  [Ki]  =  9 txM) but not to fibrinogen or iC3b- 
coated erythrocytes (data not shown). In contrast, soluble 
chondroitin  sulfate C, which also bears a  strong negative 
charge  secondary to  sulfation,  had  no  effect on  Mac-l- 
dependent  neutrophil  adhesion  to  heparin  or fibrinogen 
over a wide range of concentrations. 
Because heparins  are  a  heterogeneous  group of mole- 
cules with differences in carbohydrate backbone and  ex- 
tent of sulfation (38), we tested how neutrophils adhere to 
a series of chemically modified heparins (Fig. 6). Most hep- 
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weight  heparin.  (A)  Mac-l,  p150,95  and  ICAM-l-expressing 
CHO cells were detached, resuspended (8 ×  105 cells)  in 1 ml, 
and bound to 60-ram petri dishes  coated with spots of heparin 
and chondroitin sulfate C for 20 min at room temperature.  Un- 
bound cells  were removed after five washes with a Pasteur pi- 
pette,  and binding was quantitated  as described in Fig.  2. One 
representative  experiment  of three  is shown, and bars indicate 
standard  deviations.  (B)  Mac-expressing  CHO  cells  were  pre- 
pared and assayed as in A for binding to heparin in the presence 
of no mAb, mAb to LFA-1 (TS1/22), or mAb to Mac-1 (CBRM1/ 
26, CBRM1/27, Mn41). One representative experiment of three is 
shown, and bars indicate standard deviations. 
arins  are N-sulfated at the flee  amino group of GlcNAc, 
and  O-sulfated  at  C-6  of GIcNAc and  at  C-2  of IdoA. 
However,  some  heparins  show  additional  O-sulfation  at 
the C-2 and C-3 of GlcA or the C3 of GIcNAc. Activated 
neutrophils adhere poorly to heparins that are completely 
desulfated  (CDSNAc).  Sulfation  at the N-position of the 
glucosamine  residue  of a  completely  desulfated  heparin 
(CDSNS) restores adhesion. Although this suggests an im- 
portant  role  for  the  N-sulfate  group,  additional  motifs 
must  be  critical  because  N-desulfated  forms  of  heparin 
(NDSNAc) sustain neutrophil adhesion. 
Thus far, static adhesion assays have been used to define 
an  interaction  between  Mac-1  and  heparin.  Because 
closely related  moieties  (e.g.,  heparan  sulfate  containing 
proteoglycans) are expressed  on endothelial  cell surfaces 
in vivo, we examined how neutrophils interact with immo- 
bilized  heparin  under  conditions  of continuous  laminar 
flow.  At low, subphysiologic shear  stress  (0.36  dyn/cm2), 
neutrophils activated with the inflammatory cytokine IL-8 
bind  to  heparin.  The  adhesion  is  blocked  completely by 
mAbs to Mac-l, but not L-selectin (Fig. 7 A), even when 
20-40%  of the  L-selectin  is  retained  on  the  cell  surface 
(data not shown). At physiologic shear stress (0.7-0.8 dyn/ 
cmZ),  neutrophil  attachment  to  heparin  is  diminished. 
Resting or activated neutrophils, once adhered, do not roll 
on heparin at any shear stress examined. In contrast, neu- 
trophil rolling is supported by immobilized E- or P-selec- 
tins (35, 36), and by the L-selectin ligand, peripheral node 
in (37). Much like its interaction with ICAM-1 (35), Mac-1 
binds to heparin at subphysiologic shear flows, and attach- 
ment results in spreading and resistance to detachment at 
high physiological shear  stresses  (e.g.,  15  dyn/cm  2, Fig. 7 
B).  Similarly,  heparan  sulfate  supports  Mac-l-dependent 
firm adhesions that are highly resistant to detaching shear 
forces (Fig. 7 C). In the presence of Ca  2÷ alone, no neutro- 
phil tethering or rolling on heparan sulfate under physio- 
logic or subphysiologic shear flow was observed. 
Because  Mac-1  on neutrophils  does not attach  to hep- 
arin  under  physiologically  relevant  flow  conditions,  we 
questioned  whether  an  initial  tethering  interaction  via 
E-selectin could deaccelerate a neutrophil enough to facil- 
itate a Mac-l-heparin interaction. To dissect the different 
modes  of adhesion,  tethering  rates  and  the  shear  resis- 
tance of adhesion were measured for a substrate adsorbed 
with  E-selectin  alone  or coadsorbed  with  E-selectin  and 
heparin  (Fig. 8). Neutrophils  bind to E-selectin via coun- 
terreceptors that are decorated with sialyl Le  x (34). E-selec- 
tin sustains neutrophil  tethering, but does not support ar- 
rest  at physiologic shear  stresses  (36).  Experiments  were 
performed in buffers containing Ca  2÷ only, Ca  2+ and Mg  2÷, 
and in the presence or absence of blocking mAb to Mac-l; 
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Figure  5.  Neutrophil  adhesion  to  fibrinogen, 
high molecular weight heparin, and chondroitin 
sulfate C in the presence of soluble high molecu- 
lar weight heparin or chondroitin sulfate C. Pe- 
ripheral  blood neutrophils were resuspended (4 
x  106 cells/ml),  preincubated at room tempera- 
ture for 15  min with  varying concentrations of 
soluble  heparin  or  chondroitin  sulfate  C,  and 
added to 60-mm petri dishes coated with fibrino- 
gen,  heparin,  and  chondroitin  sulfate  C  in  the 
presence of 10  7 M fMLP. The cell-binding as- 
say, washing,  and  quantitation  were performed 
as described in Fig. 2. One representative experi- 
ment of three  is shown, and bars indicate stan- 
dard deviations. 
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of  heparin  and  chondroitin  sulfate  C.  Peripheral  blood  neu- 
trophils  were resuspended  (4  ×  10  6  cells/ml),  preincubated at 
room temperature for 15 min with mAbs, and added to 60-mm 
petri dishes  coated with  chemically  modified  forms of heparin 
(NDSNAc, N-desulfated,  N-acetylated;  CDSNS, completely de- 
sulfated,  N-sulfated;  CDSNAc,  completely desulfated,  N-acety- 
lated)  and chondroitin  sulfate  C in the absence or presence of 
10  7 M fMLP. The cell-binding assay, washing, and quantitation 
were performed as described in Fig. 2. One representative exper- 
iment of three is shown, and bars indicate standard deviations. 
selectins  require  Ca  2+,  and  leukocyte  integrins  require 
Mg  2÷ for adhesion to their respective ligands (28, 34). Un- 
der conditions of physiological shear stress (1.0 dyn/cm2), 
neutrophils do not tether on heparin substrates or on E-selec- 
tin-heparin substrates in the presence of mAbs to E-selec- 
tin (data not shown). Ca  z+ is required for neutrophil teth- 
ering  on  E-selectin  (Fig.  8  A),  but  no  firm  adhesion  or 
neutrophil  arrest develops on selectins  even in  the  pres- 
ence of Mg  2÷  (data  not  shown  and  36).  The  addition  of 
Mg  2÷  does not  affect the  rate  of tethering  to E-selectin. 
When heparin is coadsorbed with E-selectin, Ca  2+ enables 
optimal tethering and rolling as the addition of Mg  2÷ does 
not augment the tethering rate (Fig. 8 A). Mg  2÷, however, 
increases the efficiency of events that occur after tethering 
and rolling. In the absence of mAbs to Mac-l, the arrest of 
tethered and rolling neutrophils, and hence accumulation 
of cells, is increased by the addition of Mg  2+ on an E-selec- 
tin-heparin  substrate,  but  not  on  E-selectin  alone  (data 
not shown); arrest occurred immediately upon tethering or 
after a brief period of rolling. Nonarrested neutrophils roll 
at identical velocities on E-selectin or E-selectin-heparin 
substrates in the presence of Ca  2+  or Ca2+/Mg  2+, with or 
without  blocking mAbs to Mac-1.  Finally,  if neutrophils 
attach to an E-selectin-heparin substrate in the presence 
of both divalent cations at physiologic shear stresses, they 
form firm adhesions and do not detach at elevated shear 
stresses unless the Mac-1 component is blocked (Fig. 8 B). 
Collectively, these  experiments distinguish  a  Mac-l-hep- 
arin  interaction from neutrophil  rolling on selectins,  and 
suggest that neutrophil rolling on E-selectin at physiologi- 
cal shear is required so that a second, firm attachment be- 
tween Mac-1 and a  heparin ligand will occur, resulting in 
cell arrest. 
Discussion 
In  this  paper,  we  describe  a  receptor-ligand  interaction 
between the leukocyte integrin Mac-1  and  heparins.  The 
following evidence was obtained for this  interaction:  (a) 
Mac-1  that  is isolated from human  granulocytes  directly 
binds to heparin affinity resins; (b) neutrophils that are ac- 
tivated with  fMLP  or  IL-8 bind  to  heparins,  but  not  to 
other sulfated glycosaminoglycans; (c) LAD patient ncu- 
trophils that lack surface expression of Mac-1 do not bind 
heparin; (d) mAbs to Mac-l, but neither lymphocyte func- 
tion-associated antigen-1 nor L-selectin inhibit neutrophil 
attachment  to heparin  or heparan  sulfate;  and  (e)  CHO 
cells that express Mac-I bind strongly to heparin, and this 
adhesion is inhibited specifically by mAbs. 
Although interactions with carbohydrates have not been 
characterized  widely for integrins,  previous reports  indi- 
cated that Mac-1 might recognize polysaccharide determi- 
nants.  Mac-1  appears to  bind  carbohydrate  moieties  on 
yeast  13  glucan  and  bacterial  lipopolysaccharide  (56,  57, 
74),  and  more  recently,  heparin  or  heparan  sulfate  has 
been  suggested  to  interact  with  Mac-1  (13).  This  latter 
study showed that  soluble heparins  and  enzymatic treat- 
ment with heparinase inhibited the binding of CD45  and 
Mac-1  in  A4  bone  marrow-derived cell  lysates to  Swiss 
3T3 fibroblasts (13); however, no direct adhesion to hep- 
arin  by  cells  that  express  Mac-1  was  documented.  In 
contrast, we demonstrate specific adhesion  to heparin of 
neutrophils  and transfectants that express Mac-l, and no 
adhesion to heparin with LAD neutrophils that lack Mac-1 
but express CD45 (62, and data not shown). 
To  localize  the  recognition  site  of heparin  on  Mac-l, 
mAbs to defined structural epitopes were assayed for their 
capacity  to  inhibit  adhesion.  This  technique  previously 
predicted  the  200--amino acid  I  domain  as  a  recognition 
site for ICAM-1, fibrinogen, and iC3b (21). Subsequent in- 
vestigations with recombinant I domain polypeptides con- 
firm that this region participates in ligand recognition (44, 
70, 75). Inhibition experiments with mAbs suggest that hep- 
arin interacts with Mac-1 through at least one site in the I 
domain. Because fewer I domain mAbs (27% compared to 
67% for iC3b, ICAM-1, and fibrinogen) strongly block ad- 
hesion  to  heparin,  the  binding  site  may be  smaller than 
that for other characterized Mac-1 ligands. It appears that 
the recognition site for heparin may be distinct or partially 
overlapping  with  respect  to  other  Mac-1  ligands.  Two 
mAbs (14B6E.2, CBRM1/4), that abolish binding to iC3b, 
ICAM-1, and fibrinogen, do not affect binding to heparin. 
One  mAb  (CBRMI/27)  that  poorly inhibits  adhesion  to 
ICAM-1 and iC3b blocks adhesion to heparin, and soluble 
heparin does not reduce Mac-l-dependent neutrophil ad- 
hesion to fibrinogen. 
Transfectant studies in CHO cells suggest a heparin in- 
teraction with p150,95 that is lower affinity than with Mac-1. 
The p150,95  molecule is expressed at substantially lower 
levels than  Mac-1 on neutrophils,  and  this lower expres- 
sion, or greater resistance to activation by fMLP and IL-8, 
may explain the dominant role of Mac-1 on neutrophils in 
interacting with heparin. Mac-1 and p150,95 already share 
several ligands including fibrinogen (40), iC3b (10, 47, 55), 
and ICAM-1 (21). Some mesenchymal cell lines that lack 
ICAM expression bind to purified Mac-1 and p150,95 but 
not  to  lymphocyte  function-associated  antigen-1  (Dia- 
mond,  M.  A.,  and  T.  A.  Springer,  unpublished  observa- 
tions). 
Previous  studies  have  suggested  that  L-selectin  binds 
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Figure 7.  (A) Attachment of neutrophils to high molecular weight heparin 
under laminar flow. Peripheral blood neutrophils (2  x  10  7 cells/ml) were 
preincubated at room temperature for 5 min in HBSS binding media with 
mAbs (anti-Mac-1 (CBRM1/29); anti-L-selectin (DREG-56)), diluted 20- 
fold in binding media containing Ca  2÷ and Mg  2÷, and allowed to adhere to 
a heparin- or control-coated substrate in the presence of IL-8 (50 ng/ml) 
during flow at a subphysiologic  shear stress of 0.36 dyn/cm  2. After 3 min of 
continuous flow adherent neutrophils were quantitated. Data are averaged 
from two experiments, and bars indicate range. In some experiments, the 
neutrophils were pretreated with NaN3 as described in Materials and Meth- 
ods.  (B)  Detachment  assay after attachment  of neutrophils to  heparin. 
Neutrophils were  resuspended (5  ×  105  cells/ml), preincubated at room 
temperature  for  5  min  with  mAbs  (anti-Mac-1  (CBRM1/29);  anti-L- 
selectin (DREG-56)), and allowed to attach to heparin in the presence of 
IL-8 (50 ng/ml) at low flow (0.36 dyn/cm  2) for 3 min. Subsequently, shear 
stress was applied in staged increments. Neutrophils bound after 10 s at 
each indicated shear are expressed as the percentage of neutrophils that 
settled initially  on heparin. All adherent neutrophils remained stationary at 
all shear stresses. One representative experiment of three is shown. (C) De- 
tachment assay after adhesion of neutrophils to heparan sulfate. Neutro- 
phils (106/ml) were perfused at low shear flow (0.15 dyn/cm  2) and allowed 
to adhere to heparan sulfate coated substrates for 2 min in medium containing the indicated divalent cations. In some experiments, neu- 
trophils were preincubated at room temperature for 5 min with a mAb to Mac-1 (CBRM1/34). Shear stress was increased in staged in- 
crements and cells remaining bound were quantitated as described in B. Number of cells bound to a field at each indicated shear stress 
is shown. One experiment of three is shown. 
heparin-like molecules (48, 50), yet we do not  observe a 
significant contribution of this interaction in either of our 
assays. In the presence of Ca  2÷ but not Mg  2+, resting neu- 
trophils which express high levels of functional L-selectin 
do  not  interact  with  heparin  or  heparan  sulfate  under 
static or flow conditions (Fig. 7  C,  and data not shown). 
mAbs to L-selectin do not inhibit neutrophil adhesion to 
heparin or heparan sulfate (data not shown) and LAD pa- 
tient neutrophils that lack Mac-1 but express L-selectin do 
not bind heparin. Furthermore, neutrophil attachment  to 
heparin improves after stimulation with fMLP, a condition 
that prompts rapid shedding of L-selectin (31). Even when 
L-selectin is retained on the neutrophil surface, mAbs to 
Mac-1  fully abrogate the formation of firm adhesions on 
heparin and heparan sulfate. Finally, the adhesion to hep- 
arin  is  energy  and  temperature  dependent  (data  not 
shown),  requires  Mg  2+  and  low  shear  stress  flow  condi- 
tions for attachment, and is not rolling in nature. 
The  interaction between  Mac-1  and  heparin is equiva- 
lent in strength (Ki of adhesion =  9 IxM) to many other in- 
tegrin-ligand pairs (18), and the level of binding is similar 
to that of two other described Mac-1 ligands, ICAM-1 and 
fibrinogen (19, 21). Complete chemical desulfation of hep- 
arin significantly reduces binding to Mac-l, whereas N-sul- 
ration of the  amino  group  of GlcNAc restores adhesion. 
Thus, the presence of at least one type of sulfate group on 
heparin appears crucial for its interaction with Mac-1. Be- 
cause  forms  of heparin  that  lack N-sulfation (NDSNAc) 
retain the ability to bind Mac-l, secondary O-sulfated moi- 
eties, and carbohydrate structures probably contribute to 
the recognition site. Furthermore, heparan sulfate sustains 
Mac-l-dependent  adhesion  of  neutrophils;  heparan  sul- 
fate shows a  lower proportion of N-sulfated GlcNAc resi- 
dues and a  lower overall degree of O-sulfation (38). Since 
Mac-1 does not interact with chondroitin sulfates, keratan 
sulfate, or hyaluronic acid (data not shown),  the interac- 
tion  with  heparan  sulfate  glycosaminoglycans is specific, 
and does not reflect nonspecific binding to sulfate groups 
or other highly negatively charged structures. 
Although we demonstrate an in vitro adhesive interac- 
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Figure 8.  The effect of divalent cations on rolling  and firm adhesions of neutrophils tethered to E-selectin-heparin  substrate  under 
physiological shear flow. Neutrophils were suspended in a HBSS buffer containing 2 mM Ca  2+ alone, or with 1 mM Mg  2+ and perfused 
through a flow chamber at a shear of 1.05 dyn/cm  2. (A) Neutrophil tethering events (cell attachments of at least 2 s duration) were deter- 
mined on substrates adsorbed with  recombinant E-selectin alone or with heparin. Tethering is expressed as the number of tethering 
events per minute per field (0.43 mm  2 in area). Cells were preincubated with anti-Mac-1 mAb (CBRM1/34) or control anti-HLA class I 
mAb (W6/32) for 5 min before perfusion into the chamber. Results are expressed as the mean _+ range. (B) After 1 min of cell perfusion 
at a shear of 1.05 dyn/cm  2 that allowed accumulation of tethered cells, the flow rate was increased, and the number of cells that remained 
bound to the substrate was measured. The data is expressed as the percentage of the initially  bound neutrophils. For blocking experi- 
ments, cells were preincubated with mAbs to Mac-1 and HLA class I as described above. The control mAb had no effect on neutrophil 
tethering, rolling, or arrest.  Results in A and B are representative of three separate experiments. 
tion  between  purified  heparins  and  Mac-l,  the  form  to 
which Mac-1 binds in vivo remains unknown. Physiologi- 
cally,  heparins  decorate  proteoglycans,  molecules  that 
function broadly in cell adhesion  and communication (9, 
58).  Many  cell  surface  and  matrix-associated  proteogly- 
cans contain heparan sulfate,  a  less sulfated form of hep- 
arin (38, 58), whereas those found in intracellular granules 
of some leukocytes contain the more highly sulfated hep- 
arin  molecule  (68).  Candidate  proteoglycan  ligands  that 
display  heparan  sulfate  include  syndecans,  perlecan,  and 
glypican (14, 42, 49, 59).  Syndecans are an evolutionarily 
related gene family of four transmembrane proteoglycans, 
and are expressed  broadly in epithelial,  endothelial,  con- 
nective, and neural tissues (30). A  common ancestral gene 
family member in Drosophila colocalizes with integrins at 
sites  of  muscle  attachment  during  wing  morphogenesis 
(26, 64).  Antimicrobial  peptides  generated during wound 
repair induce expression of syndecans on endothelial cells, 
fibroblasts,  and in the surrounding extracellular  matrix of 
granulation  tissue  (24).  Perlecan  is  a  basal  lamina  trans- 
membrane  proteoglycan  involved  in  neovascularization 
(6), and has been suggested to interact with both [31 and 133 
integrins in a heparin-dependent  manner (27). Glypican is 
a  heparan  sulfate  proteoglycan that  is  membrane  linked 
through a glycosyl phosphatidylinositol anchor (14), and is 
expressed  on  aortic  and  umbilical  vein  endothelial  cells 
(43).  Future  studies  will  assess  which  of  the  described 
heparan  sulfate  proteoglycans  serve  as  adhesive  ligands 
for  Mac-1.  Preliminary  studies  indicate  a  high  level  of 
specificity of Mac-1  and heparan  sulfate  proteoglycan in- 
teractions; the purified extracellular domain of syndecan-1 
(29), which is expressed primarily on epithelial cells  (30), 
does not support neutrophil adhesion (Alon, R., and T. A. 
Springer, unpublished observations). 
Where  could  a  Mac-l-heparin  interaction  be  impor- 
tant?  It may contribute  to  neutrophil  migration  through 
the  endothelium  during  inflammation.  The  laminar  flow 
experiments  suggest  that  Mac-1  does not make  transient 
interactions  with  heparin  or heparan  sulfate  that  charac- 
terize  rolling; at physiological shear stresses,  activated  or 
resting neutrophils do not attach to heparin substrates.  In 
contrast,  at  conditions of low shear stress,  activated  neu- 
trophils  attach  to  and  spread  on  heparins  in  a  Mac-i- 
dependent  manner,  similar  to that  observed  on ICAM-1 
(35).  At high shear  flows, when E-selectin  is coadsorbed 
with  heparin,  neutrophils  make  transient  rolling  attach- 
ments via selectins, and then arrest and develop high shear 
resistance through a  heparin-Mac-1  interaction.  We have 
no evidence for an overlap between selectin- and Mac-l- 
mediated  adhesion  to heparin;  Mac-1  binding to heparin 
does not support neutrophil rolling. Instead, it enables the 
firm  adhesion  of cells  that  have  been slowed  physiologi- 
cally  by  selectin-mediated  rolling,  or  allowed  sufficient 
contact time experimentally  by binding at subphysiologic 
flow.  Because  they  bind  inflammatory  cytokines  and 
chemokines  such  as  IL-8  (66,  71),  heparins  can  both 
present molecules that activate Mac-1 and serve as ligands 
for adhesion  and  spreading.  Thus,  heparin  moieties  may 
complement other receptors such as ICAM-1 in the Mac- 
1-mediated neutrophil extravasation process. 
Another role for a Mac-l-heparin interaction may be in 
neutrophil migration after extravasation. Heparan sulfates 
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secreted proteoglycans, and may serve  as adhesive tracks 
for  migration  and  haptotaxis  of leukocytes  that express 
Mac-1.  In addition, heparin-containing proteoglycans re- 
side  within primary granules  of resting neutrophils  (53). 
After activation, these molecules translocate to the surface 
and  into  the  surrounding  environment.  A  chemotactic 
stimulus in the periphery may induce neutrophils to acti- 
vate Mac-1 and directionally secrete an adhesive ligand to 
create a path for locomotion. 
A  Mac-l-heparin interaction also may explain the phe- 
nomenon of neutrophil homotypic aggregation. Activation 
by high concentrations of certain chemotactic factors (e.g., 
fMLP) induces neutrophil degranulation, activation of sur- 
face Mac-1 (17), and a Mac-l-dependent homotypic adhe- 
sion (54). Because neutrophil granules contain proteogly- 
cans, such as serglycin, that display polyvalent heparin-like 
moieties  (41, 53), degranulation may promote homotypic 
aggregation by bridging Mac-1 on adjacent cells. Interest- 
ingly,  neutrophil  aggregation  does  not  occur  at  16°C,  a 
temperature that prevents degranulation, but is permissive 
for the activation of neutrophil Mac-1  (61, and Diamond, 
M. S., and T. A. Springer, unpublished observations). 
In this report we  have  described  a  specific  interaction 
between heparin, heparan sulfate, and the leukocyte inte- 
grin Mac-1. Future studies must aim at identifying the pre- 
cise functional side chain on heparan sulfate glycans that 
binds to Mac-l, the proteoglycans that are decorated with 
this moiety, and the biological context for Mac-l-heparin 
adhesion. Such information may enable the generation of 
heparin or heparan sulfate analogues that serve selectively 
as antiinflammatory agents in vivo. 
The authors thank J. Bickford for superb technical assistance, D. Ander- 
son and the LAD patients for providing access to CD18-deficient neutro- 
phils, and M. Bernfield for his generous gift of purifed syndecan-1. 
This  work was  supported  by  National  Institutes  of  Health  grants 
(T32GM07753-11,  CA31799, and AR40929), a Crohn's & Colitis Founda- 
tion of America research grant, and an Arthritis Foundation Biomedical 
Science grant. 
Received for publication 17 March 1995 and in revised form 7 June 1995. 
References 
1. Altieri, D. C., and T. S. Edgington. 1988. The saturatable high affinity asso- 
ciation of factor X  to ADP-stimulated monocytes defines a  novel func- 
tion of the Mac-1 receptor. J. Biol. Chem. 263:7007-7015. 
2. Altieri, D. C., R. Bader, P. M. Mannucci, and T. S. Edgington. 1988. Oli- 
gospecificity of the cellular adhesion receptor MAC-1 encompasses an 
inducible recognition specificity for fibrinogen. J.  Cell BioL  107:1893- 
1900. 
3. Anderson, D. C., and T. A. Springer. 1987. Leukocyte adhesion deficiency: 
an  inherited  defect  in  the  Mac-l,  LFA-1,  and  p150,95 glycoproteins. 
Annu. Rev. Med. 38:175-194. 
4. Anderson, D. C., L  J. Miller, F. C. Schmalsteig, R. Rothlein, and T. A. 
Springer. 1986. Contributions of the Mac-1 glycoprotein family to adher- 
ence-dependent  granulocyte  functions:  structure-function  assessment 
employment subunit-specific monoclonal antibodies. J.  lmmunol,  137: 
15-27. 
5. Arnaout, M. A., R. F. Todd, III, N. Dana, J. Melamed, S. F. Schlossman, 
and H. R. Colten. 1983. Inhibition of phagocytosis of complement C3- or 
immunoglobulin G-coated particles and of C3bi binding by monoclonal 
antibodies to a monocyte-granulocyte membrane glycoprotein (Mol). J. 
Clin. Invest. 72:171-179. 
6. Aviezer, D., D. Hecht, M. Safran, M. Elsinger, G. David, and A. Yayon. 
1994.  Perlecan,  basal  lamina  proteoglycan, promotes  basic  fibroblast 
growth factor-receptor binding, mitogenesis, and angiogenesis. Cell.  79: 
1005-1013. 
7. Barnstable, C. J., W. F. Bodmer, G. Brown, G. Galfre, C. Milstein, A. F. 
Williams, and A. Ziegler. 1978. Production of monoclobal antibodies to 
group A  erythrocytes, HLA, and other human cell surface antigens--new 
tools for genetic analysis. CelL  14:9-20. 
8. Belier, D. I., T. A. Springer, and R. D. Schreiber. 1982. Anti-Mac-1 selec- 
tively inhibits the mouse and human type three complement receptor. J. 
Exp. Med. 156:1000-1009. 
9. Bernfield, M., R. Kokenyesi, M. Kato, M. T. Hinkes, J. Spring, R. L. Gallo, 
and E. J. Lose.  1992. Biology of the syndecans: a  family of transmem- 
brane heparan sulfate proteoglycans. Annu. Rev. Cell Biol. 8:365-393. 
10.  Bilsland, C. A., M. S. Diamond, and T. A. Springer. 1994. The leukocyte in- 
tegrin p150,95 (CDllc/CD18) acts as a receptor for iC3b. Activation by a 
heterologous 13 subunit and localization of a ligand recognition site to the 
I domain. J. lmmunol.  152:45824589. 
11. Butcher,  E.  C.  1991.  Leukocyte-endothelial cell  recognition:  three  (or 
more) steps to specificity and diversity. Cell.  67:1033-1036. 
12. Carlos, T. M., and J. M. Harlan. 1990. Membrane proteins involved in pha- 
gocyte adherence to endothelium, lmmunol. Rev. 114:1-24. 
13. Coombe, D. R., S. M. Watt, and C. R. Parish. 1994. Mac-1 (CDllb/CD18) 
and CD45  mediate  the  adhesion  of hematopoietic progenitor cells to 
stromal cell elements via recognition of stromal heparan sulfate. Blood. 
84:739-752. 
14. David, G., V. Lories, B. Decock, P. Marynen, J.-J. Cassiman, and H. Van 
den Berghe. 1990. Molecular cloning of a phosphatidylinositol-anchored 
membrane heparan sulfate proteoglycan from human lung fibroblasts. J. 
Cell Biol. 111:3165-3176. 
15.  de Fougerolles, A. R., S. A. Stacker, R. Schwarting, and T. A. Springer. 
1991.  Characterization of ICAM-2  and evidence  for  a  third  counter- 
receptor for LFA-1. J. Exp. Med. 174:253-267. 
16.  de Fougerolles, A. R., L. B. Klickstein, and T. A. Springer. 1993. Cloning 
and expression of intercellular adhesion molecule 3 reveals a strong ho- 
mology to other immunoglobulin family counter-receptors for lympho- 
cyte function-associated antigen 1. J. Exp. Med. 177:1187-1192. 
17. Diamond,  M.  S.,  and T.  A.  Springer.  1993. A  subpopulation  of Mac-1 
(CDllb/CD18) molecules mediates neutrophil adhesion to ICAM-1 and 
fibrinogen. J. Ceil'Biol.  120:545-556. 
18. Diamond, M. S., and T. A. Springer. 1994. The dynamic regulation of inte- 
grin adhesiveness. Curt Biol. 4:506-517. 
19. Diamond, M.  S., D. E.  Staunton, A. R. de Fougerolles, S. A. Stacker, J. 
Garcia-Aguilar, M. L. Hibbs, and T. A. Springer. 1990. ICAM-1 (CD54): 
a counter receptor for Mac-1 (CDllb/CD18). Z  Cell Biol. 111:3129-3139. 
20. Diamond, M. S., D. E. Staunton, S. D. Marlin, and T. A. Springer. 1991. 
Binding of the integrin Mac-1 (CDllb/CD18) to the third Ig-like domain 
of ICAM-1 (CD54) and its regulation by glycosylation. Cell. 65:961-971. 
21. Diamond, M. S., J. Garcia-Aguilar, J. K. Bickford, A. L. Corbi, and T. A. 
Springer. 1993. The I domain is a major recognition site on the leukocyte 
integrin Mac-1 (CDllb/CD18) for four distinct adhesion ligands. J. Cell 
Biol. 120:1031-1043. 
22. Eddy, A., S. L. Newman, F. Cosio, T. LeBien, and A. Michael. 1984. The 
distribution of the CR3 receptor on human cells and tissue as revealed by 
a monoclonal antibody. Clin. Immunol. lmmunopathol.  31:371-389. 
23. Entman, M. L., K. Youker, S.  B. Shappell, C. Siegel, R. Rothlein, W. J. 
Dreyer, F. C. Schmalstieg, and C. W. Smith. 1990. Neutrophil adherence 
to isolated adult canine myocytes: evidence for a CD18-dependent mech- 
anism. J. Clin. Invest. 85:1497-1506. 
24. Gallo, R. L., M. Ono, T. Povsic, C. Page, E. Eriksson, M. Klagsbrun, and 
M.  Bernfield.  1994. Syndecans, cell surface heparan sulfate proteogly- 
cans, are induced by a  proline-rich antimicrobial peptide from wounds. 
Proc. Natl. Acad. Sci.  USA. 91:11035-11039. 
25. Gerard, C., and N.  P.  Gerard. 1994. The  pro-inflammatory seven trans- 
membrane segment receptors of the leukocyte. Curr. Opin. Immunol.  6: 
140-145. 
26. Gotwals, P. J., S. E. Paine-Saunders, K. A. Stark, and R. O. Hynes. 1994. 
Drosophila integrins and their ligands. Curr. Opin. Cell Biol. 6:734-739. 
27. Hayashi, K., J. A. Madri, and P. D. Yurchenco. 1992. Endothelial cells in- 
teract with the core protein of basement membrane perlecan through 131 
and 133 integrins: an adhesion modulated by glycosaminoglycan.  J.  Cell 
Biol. 119:945-959. 
28. Hynes, R. O. 1992. Integrins: versatility, modulation, and signalling in cell 
adhesion. Cell, 69:11-25. 
29. Kato, M., H. Wang, M. Bernfield, J. T. Gallagher, and J. E. Turnbull. 1994. 
Cell surface syndecan-1 on distinct cell types differs in fine structure and 
ligand binding of its heparan sulfate chains. Z  BioL  Chem.  269:18881- 
18890. 
30. Kim, C. W., O. A. Goldberger, R. L. Gallo, and M. Bernfield. 1994. Mem- 
bers of the  syndecan family of heparan sulfate proteoglycans are  ex- 
pressed in distinct cell-, tissue-, and development-specific patterns. Mol. 
Biol. Cell. 5:797-805. 
31. Kishimoto, T. K., M. A. Jutila, E. L. Berg, and E. C. Butcher. 1989. Neutro- 
phil  Mac-1  and MEL-14  adhesion proteins are  inversely regulated by 
chemotactic factors. Science (Wash. DC). 245:1238-1241. 
32. Kishimoto, T. K., R. S. Larson, A. L. Corbi, M. L. Dustin, D. E. Staunton, 
and T. A. Springer. 1989. The leukocyte integrins: LFA-1, Mac-l, and 
p150,95. Adv. Irnmunol. 46:149-182. 
33. Kishimoto, T. K., M. A. Jutila, and E. C. Butcher. 1990. Identification of a 
human peripheral lymph node homing receptor: a  rapidly down-regu- 
lated adhesion molecule. Proc. Natl. Acad. Sci.  USA. 87:2244-2248. 
Diamond et al. Heparin Is an Adhesive Ligand for Mac-1 ( CD  l l b/CD18)  1481 34. Lasky, L. A. 1992. Selectins: interpreters of cell-specific carbohydrate in- 
formation during inflammation. Science (Wash. DC). 258:964-969. 
35. Lawrence, M. B., and T. A. Springer. 1991. Leukocytes roll on a selectin at 
physiologic flow rates:  distinction from the  prerequisitie  for adhesion 
through integrins. Cell. 65:859-873. 
36. Lawrence, M. B., and T. A. Springer. 1993. Neutrophils roll on E-selectin. 
J. lmmunol, 151:6338-6346. 
37. Lawrence, M. B., E. L. Berg, E. C. Butcher, and T. A. Springer. 1995. Roll- 
ing of lymphocytes and neutrophils on peripheral node addressin and 
subsequent arrest on ICAM-1 in shear flow. Eur J. ImmunoL 25:1025- 
1031. 
38. Lindahl, U., and L. Kjellen. 1991. Heparin or heparan sulfate--what is the 
difference. Thromb. Haemostasis. 66:44M8. 
39. Lo, S. K., G. A. Van Seventer, S. M. Levin, and S. D. Wright. 1989. Two 
leukocyte receptors (CDlla/CD18 and CDllb/CD18) mediate transient 
adhesion to endothelium by binding to different ligands. J. lmmunol. 143: 
3325-3329. 
40. Loike, J. D., B. Sodeik, L. Cao, S. Leucona, J. I. Weitz, P. A. Detmers, S. D. 
Wright, and S. C. Silverstein. 1991. CDllc/CD18 on neutrophils recog- 
nizes a domain at the N  terminus of the Ac~ chain on fibrinogen. Proc. 
NatL Acad. Sci.  USA. 88:1044-1048. 
41. Maillet, P., P. M. Alliel, M. J. Mitjavila, J. P. Perin, P. Jolles, and F. Bonnet. 
1992. Expression of the serglycin gene in human leukemic cell lines. Leu- 
kemia (Baltimore). 6:1143-1147. 
42. Mali, M., P. Jaakkola, A. Arvilommi, and M. Jalkanen. 1990. Sequence of 
human syndecan indicates a novel gene family of integral membrane pro- 
teoglycans. Z  Biol,  Chem. 265:6884-6889. 
43. Mertens,  G., J.  J.  Cassiman, H.  Van den  Berghe, J.  Vermylen,  and G. 
David. 1992. Cell surface heparan sulfate proteoglycans from human vas- 
cular endothelial cells..L Biol.  Chem. 267:20435-20443. 
44. Michishita, M., V. Videm, and M. A. Arnaout. 1993. A novel divalent cation- 
binding site in the A  domain of the [32 integrin CR3 (CDllb/CD18) is es- 
sential for ligand binding. Cell. 72:857-867. 
45. Miller, L. J., R. Schwarting, and T. A. Springer. 1986. Regulated expression 
of the Mac-l, LFA-1, p150,95 glycoprotein family during leukocyte dif- 
ferentiation. J. lmmunol. 137:2891-2900. 
46. Miller, L. J., D. F. Bainton, N. Borregaard, and T. A. Springer. 1987. Stimu- 
lated mobilization of monocyte Mac-1  and p150,95 adhesion proteins 
from an intracellular vesicular compartment to the cell surface. Z  Clin. 
Invest. 80:535-544. 
47. Myones, B. L., J. G. Dalzell, N. Hogg, and G. D. Ross. 1988. Neutrophil 
and monocyte cell surface p150,95 has iC3b-receptor (CR4) activity re- 
sembling CR3. Z  Clin. Invest. 82:640~651. 
48. Nelson, R. M., O. Cecconi, W. G. Roberts, A. Aruffo, R. J. Linhardt, and 
M. P. Bevilacqua. 1993. Heparin oligosaccharides bind L- and P-selectin 
and inhibit acute inflammation. Blood. 82:3253-3258. 
49. Noonan, D. M., A. Fuller, P. Valente, S. Cai, E. Horigan, M. Sasaki, Y. Ya- 
mada, and J.  R. Hassell.  1991. The  complete sequence of perlecan, a 
basement  membrane  heparan  sulfate  proteoglycan, reveals  extensive 
similarity with laminin A  chain, low density lipoprotein receptor, and the 
neural cell adhesion molecule. J. Biol.  Chem. 266:22939-22947. 
50. Norgard-Sumnicht, K.  E.,  N.  M.  Varki,  and  A.  Varki.  1993.  Calcium- 
dependent heparin-like ligands for L-selectin in nonlymphoid endothelial 
cells. Science (Wash. DC). 261:480483. 
51. Parkos, C. A., R. A. Allen, C. G. Cochrane, and A. J. Jesaitis. 1987. Puri- 
fied cytochrome b  from human granulocyte plasma membrane is com- 
prised of two polypeptides with relative molecular weights of 91,000 and 
22,000. J. Clin. Invest.  80:732-742. 
52. Parkos, C. A., C. Delp, M. A. Arnaout, and J. L. Madara. 1991. Neutrophil 
migration  across  a  cultured  intestinal  epithelium:  dependence  on  a 
CDllb/CD18-mediated event and enhanced efficiency in physiological 
direction. J. Clin. Invest. 88:1605-1612. 
53. Parmley, R. T., R. E. Hurst, M. Takagi, S. S. Spicer, and R. L. Austin. 1983. 
Glycosaminoglycans  in human neutrophils and leukemic myeloblasts: ul- 
trastructural, cytochemical, immunologic, and biochemical characteriza- 
tion. Blood. 61:257-266. 
54. Patarroyo, M., P. G. Beatty, N. Serhan, and C. G. Gahmberg. 1985. Identi- 
fication of a cell-surface glycoprotein mediating adhesion in human gran- 
ulocytes. Scand.  J. lmmunol. 22:619-631. 
55. Postigo, A. A., A. L. Corbi, F. S~inchez-Madrid, and M. O. De Land~izuri. 
1991. Regulated expression and function of CDllc/CD18 integrin on hu- 
man B lymphocytes. Relation between attachment to fibrinogen and trig- 
gering of proliferation through CDllc/CD18. J.  Exp.  Med.  174:1313- 
1322. 
56. Ross, G. D., J. A. Cain, and P. J. Lachmann. 1985. Membrane complement 
receptor type three (CR3) has lectin-like properties analagous to bovine 
conglutinin and functions as a receptor for zymosan and rabbit erythro- 
cytes as well as a receptor for iC3b. J. lmmunol. 134:3307-3315. 
57. Ross, G. D., J. A. Cain, B. L. Myones, S. L. Newman, and P. J. Lachmann. 
1987. Specificity of membrane complement receptor type three (CR3) for 
[3-glucans. Complement. 4:61-74. 
58. Ruoslahti, E.  1988. Structure and biology of proteoglycans. Annu.  Rev. 
Cell, Biol.  4:229-255. 
59. Saku, T., and H. Furthmayr. 1989. Characterization of the major heparan 
sulfate proteoglycan secreted by bovine aortic endothelial cells in cul- 
ture. J. Biol. Chem. 264:3514-3523. 
60. S~inchez-Madrid,  F.,  A.  M.  Krensky,  C.  F.  Ware,  E.  Robbins,  J.  L. 
Strominger, S. J. Burakoff, and T. A. Springer. 1982. Three distinct anti- 
gens associated with human T  lymphocyte-mediated cytolysis: LFA-1, 
LFA-2, and LFA-3. Proc. Natl. Acad. Sci.  USA. 79:7489-7493. 
61. Schleiffenbaum, B., R. Moser, M. Patarroyo, and J. Fehr.  1989. The cell 
surface glycoprotein Mac-1  (CDllb/CD18)  mediates neutrophil adhe- 
sion and modulates degranulation independently of its quantitative cell 
surface expression. J. lmmunoL 142:3537-3545. 
62. Schwinzer, R.  1989. Cluster report:  CD45/CD45R. In  Leucocyte Typing 
IV:  White  Cell  Differentiation  Antigens.  W.  Knapp,  B.  Dorken,  W. 
Gilks, E. Rieber, R. Schmidt, H. Stein, and A. von dem Borne, editors. 
Oxford University Press, Oxford, UK. 628-634. 
63. Smith, C. W., S. D. Marlin, R. Rothlein, C. Toman, and D. C. Anderson. 
1989. Cooperative interactions of LFA-1 and Mac-1 with intercellular ad- 
hesion molecule-1 in facilitating adherence and transendothelial migra- 
tion of human neutrophils in vitro. J. Clin. Invest.  83:2008-2017. 
64. Spring, J.,  S.  E.  Paine-Saunders, R.  O.  Hynes, and M.  Bernfield.  1994. 
Drosophila syndecan: conservation of a cell-surface heparan sulfate pro- 
teoglycan. Proc. Natl. Acad. Sci.  USA. 91:3334-3338. 
65. Springer, T.  A. 1990. Adhesion receptors of the  immune system. Nature 
(Wash. DC). 346:425~-33. 
66. Springer, T. A. 1994. Traffic signals for lymphocyte recirculation and leu- 
kocyte emigration: the multistep paradigm. Cell. 76:301-314. 
67. Stacker,  S.  A.,  and  T.  A.  Springer.  1991.  Leukocyte  integrin  p150,95 
(CDllc/CD18) functions as an adhesion molecule binding to a counter- 
receptor on stimulated endothelium. J. lmmunol' 146:648-655. 
68. Stevens, R. L., K. Otsu, J. H. Weis, R. V. Tantravahi, and K. F. Austen. 
1987. Co-sedimentation of chondroitin sulfate A glycosaminoglycans  and 
proteoglycans with the cytolytic secretory granules of rat large granular 
lymphocyte (LGL) tumor cells, and identification of a mRNA in normal 
and transformed LGL that encodes proteoglycan. Z  lmmunol.  139:863- 
868. 
69. Uciechowski, P., and R. Schmidt. 1989. Cluster report: CDll. In Leucocyte 
Typing IV: White Cell Differentiation Antigens. W. Kuapp, B. Dorken, 
W. Gilks, E. Rieber, R. Schmidt, H. Stein, and A. von dem Borne, edi- 
tors. Oxford University Press, Oxford, UK. 543-551. 
70. Ueda, T., P. Rieu, J. Brayer, and M. A. Arnaout. 1994. Identification of the 
complement iC3b binding site in the  [32 integrin CR3 (CDllb/CD18). 
Proc. Natl. Acad. Sci.  USA. 91:10680-10684. 
71. Webb, L. M. C., M. U. Ehrengruber, I. Clark-Lewis, M. Baggiolini, and A. 
Rot. 1993. Binding to heparan sulfate or heparin enhances neutrophil re- 
sponses to interleukin 8. Proc. Natl. Acad. Sci.  USA. 90:7158-7162. 
72. Wright, S. D., P.  E.  Rao, W.  C. Van Voorhis, L. S.  Craigmyle, K. Iida, 
M. A. Talle, E. F. Westberg, G. Goldstein, and S. C. Silverstein. 1983. 
Identification of the  C3bi  receptor  of human monocytes and  macro- 
phages with monoclonal antibodies. Proc. Natl. Acad. Sci.  USA. 80:5699- 
5703. 
73. Wright, S. D., J. I. Weitz, A. J. Huang, S. M. Levin, S. C. Silverstein, and 
J.D.  Loike.  1988. Complement  receptor type three  (CDllb/CD18)  of 
human polymorphonuclear leukocytes recognizes fibrinogen. Proc. Natl. 
Acad. Sci.  USA. 85:7734-7738. 
74. Wright, S. D., S. M. Levin, M. T. C. Jong, Z. Chad, and L. G. Kabbash. 
1989. CR3  (CDllb/CD18)  express one binding site for Arg-Gly-Asp- 
containing peptides and a second site for bacterial lipopolysaccharide.  Z 
Exp. Med. 169:175-183. 
75. Zhou, L., D. H. S. Lee, J. Plescia, C. Y. Lau, and D. C. Altieri. 1994. Differ- 
ential ligand binding specificities of recombinant CD f 1  b/CD 18 i  ntegrin I 
domain. J. Biol,  Chem. 269:17075-17079. 
The Journal of Cell Biology, Volume 130, 1995  1482 